Finding: Semaglutide reduced the risk of major kidney events by 24% and major cardiovascular events by 18%
Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
Generally, Tirzepatide promotes weight loss by reducing appetite
Pills seem to result in similar side effect profiles compared to injectables, according to Yale Medicine
For more storage context, review our how to store compounded semaglutide or tirzepatide at home guide
1 Introduction Drugs that activate the glucagon-like peptide-1 (GLP-1) receptor are currently used clinically to treat type 2 diabetes mellitus (T2DM) and obesity (Nauck et al., 2021)
